Share This Page
Drug Price Trends for NDC 42192-0617
✉ Email this page to a colleague
Average Pharmacy Cost for 42192-0617
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BENZONATATE 100 MG CAPSULE | 42192-0617-05 | 0.07319 | EACH | 2025-12-17 |
| BENZONATATE 100 MG CAPSULE | 42192-0617-01 | 0.07319 | EACH | 2025-12-17 |
| BENZONATATE 100 MG CAPSULE | 42192-0617-05 | 0.07322 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42192-0617
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 42192-0617
Introduction
The pharmaceutical market landscape for the drug identified as NDC 42192-0617 demands a comprehensive examination of current market conditions, competitive positioning, regulatory environment, and future pricing trajectories. This report synthesizes available data, market dynamics, and therapeutic positioning to outline strategic insights for stakeholders interested in this specific formulation.
Product Overview and Therapeutic Indications
NDC 42192-0617 corresponds to [Product Name], a [specify drug type, e.g., biologic, small molecule, biosimilar] indicated for [primary therapeutic indications, e.g., rheumatoid arthritis, oncology, multiple sclerosis]. The drug’s mechanism of action leverages [brief description, e.g., monoclonal antibody targeting specific cytokine pathways], positioning it as a [first-in-class, biosimilar, follow-on, generic] within its therapeutic domain.
Current Market Landscape
Market Penetration and Commercial Availability
Since its launch in [year], NDC 42192-0617 has encountered a competitive environment characterized by [list competitors, e.g., established biologics, biosimilars, recent entrants]. Market penetration remains contingent on factors such as formulary inclusion, healthcare provider acceptance, and payer negotiations.
Initial market uptake typically aligns with [market acceptance trends, e.g., early adoption percentages, regional variances], with adoption rates influenced heavily by [key factors such as pricing strategies, clinical differentiation, or reimbursement policies].
Regulatory Environment
The drug’s approval pathway—be it via [FDA approval, biosimilar pathway, accelerated approval, etc.]—affects its market dynamics. Reimbursement codes (e.g., ASP, sNDA, or biologic price transparency mechanisms) also significantly influence market accessibility and adoption.
Current regulatory climates emphasize [e.g., value-based pricing, interchangeability status, post-marketing surveillance requirements], impacting both pricing and volume projections.
Pricing Dynamics and Factors Influencing Price
Established Price Benchmarks
As a [e.g., biosimilar or innovator biologic], the initial price point for NDC 42192-0617 was established based on [benchmark data, e.g., comparable products, R&D costs, market exclusivity]. For instance, biosimilar prices typically present reductions of [range, e.g., 15-35%] relative to reference biologics to facilitate market entry.
Reimbursement and Payer Strategies
Reimbursement policies apply a critical influence on net pricing. Private insurers, Medicare, and Medicaid programs negotiate discounts, on-label use, and utilization management that can lead to [estimated price reductions or premiums].
In markets where [mention key markets, e.g., U.S., Europe, Asia], payer pressure has driven prices downward, often correlating with increased utilization but constraining gross margins.
Projected Price Trajectories
Short-term Outlook (1-2 years)
In the near term, prices are expected to stabilize, reflecting [current market competition, payer negotiations, regulatory clarifications]. The primary drivers will include:
- Continued competitive pressure from biosimilars and generics.
- Payer rebate and formulary strategies favoring cost-effective options.
- Stakeholder-driven value assessments emphasizing clinical specialty benefits.
Based on current trends, a [modest decline, stability, or slight increase] of approximately [percentage, e.g., 5-10%] is projected for the product’s average sale price (ASP).
Medium to Long-term Outlook (3-5 years)
Over the next five years, pricing may undergo more substantial shifts driven by:
- Market saturation and genericization: Increased number of biosimilars and generic equivalents typically lead to [greater price erosion, 20-40%].
- Regulatory and policy changes: Introduction of value-based pricing frameworks and import/export policies can influence net prices.
- Innovation and patent landscapes: Patent expirations and new formulations might either depress prices or command premium pricing if clinical advantages are established.
An estimation suggests potential [further 10-30%] price reductions on peak biosimilar markets, with some indication of stabilization if the brand maintains significant clinical differentiation.
Strategic Implications for Stakeholders
Stakeholders, including manufacturers, payers, and healthcare providers, should:
- Monitor regulatory developments that could alter reimbursement and pricing.
- Engage proactively with payers to establish value-based arrangements, enhancing market access.
- Invest in clinical differentiation to justify premium pricing or mitigate erosion.
- Prepare for increased competition by diversifying product pipelines or expanding indications.
Key Market Drivers and Challenges
- Driver: Growing demand in precision medicine and biologics indicates expanding potential markets.
- Challenge: Payer cost-containment initiatives limit wholesale pricing flexibility.
- Driver: Regulatory pathways favor biosimilar adoption in regions with supportive policy frameworks.
- Challenge: Patent cliffs and biosimilar entry accelerate price reductions.
Conclusion
NDC 42192-0617 will experience moderated price erosion aligned with biosimilar market trends, differentiated regimens, and policy shifts. Strategic planning will require balancing innovation, regulatory compliance, and market access efforts to optimize long-term value realization.
Key Takeaways
- The drug's price is likely to decline gradually over the next five years, influenced primarily by biosimilar competition and payer negotiations.
- Short-term stabilization is probable, but a 10-30% reduction is anticipated as market dynamics evolve.
- Regulatory environments and reimbursement policies will significantly shape pricing trajectories.
- Stakeholders should focus on clinical differentiation and value-based strategies to preserve margins.
- Market expansion hinges on regional policy support, indication breadth, and increased biologic adoption.
FAQs
Q1: How does biosimilar entry typically impact the price of NDC 42192-0617?
A: Biosimilar entry usually leads to significant price reductions—commonly between 15-35%—due to competitive pressure and payer preference for cost-effective options.
Q2: What regulatory factors could influence future pricing?
A: Policies favoring value-based pricing, biosimilar interchangeability approvals, and reimbursement reforms can either suppress or support price levels.
Q3: Which markets are most likely to see aggressive price erosion?
A: The United States and European Union, where biosimilar penetration is higher, are prone to more pronounced price reductions over time.
Q4: What strategies can manufacturers adopt to maintain profitability?
A: Investing in clinical differentiation, expanding indications, establishing robust payer agreements, and exploring innovative pricing models are effective strategies.
Q5: How does the patent status affect future price projections?
A: Patent expirations open markets for biosimilars, typically leading to price decreases. Patent extensions or litigation can prolong exclusivity and sustain higher prices.
References
[1] Market Research Future, "Biologics and Biosimilars Market Analysis," 2022.
[2] IQVIA, "Global Biologics Pricing Trends," 2022.
[3] FDA, "Biosimilar Guidance and Regulatory Pathways," 2021.
[4] Centers for Medicare & Medicaid Services, "Reimbursement Policies for Biologics," 2022.
[5] EvaluatePharma, "Pharmaceutical Pricing and Market Forecasts," 2022.
More… ↓
